These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19200218)

  • 41. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction.
    Kullberg-Lindh C; Ascher H; Saalman R; Olausson M; Lindh M
    Pediatr Transplant; 2006 Feb; 10(1):83-9. PubMed ID: 16499593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus.
    Koch DG; Christiansen L; Lazarchick J; Stuart R; Willner IR; Reuben A
    Liver Transpl; 2007 Jun; 13(6):904-12. PubMed ID: 17539010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort.
    Baiocchi OC; Colleoni GW; Caballero OL; Vettore AL; Andrade AL; Pestana JO
    Haematologica; 2004 Mar; 89(3):366-8. PubMed ID: 15020282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
    Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring.
    Elidemir O; Kancherla BS; Schecter MG; McKenzie ED; Morales DL; Heinle JS; Mallory GB
    Pediatr Transplant; 2009 Aug; 13(5):606-10. PubMed ID: 19017289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
    Gotoh K; Ito Y; Ohta R; Iwata S; Nishiyama Y; Nakamura T; Kaneko K; Kiuchi T; Ando H; Kimura H
    J Infect Dis; 2010 Aug; 202(3):461-9. PubMed ID: 20560768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphoproliferative disease after allogeneic stem cell transplantation--pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum.
    Aalto SM; Juvonen E; Tarkkanen J; Volin L; Ruutu T; Mattila PS; Piiparinen H; Knuutila S; Hedman K
    J Clin Virol; 2003 Dec; 28(3):275-83. PubMed ID: 14522066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
    Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular epidemiology of Epstein-Barr virus in adult kidney transplant recipients.
    Cavallo R; Elia M; Gruosso V; Curtoni A; Costa C; Bergallo M
    Transplant Proc; 2010 Sep; 42(7):2527-30. PubMed ID: 20832536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis.
    Saueressig MG; Boussaud V; Amrein C; Guillemain R; Souilamas J; Souilamas R
    Clin Transplant; 2011; 25(4):E430-6. PubMed ID: 21518001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.
    Fukushima D; Sato K; Kawagishi N; Ohuchi N; Satomi S
    Transplantation; 2015 Jan; 99(1):114-9. PubMed ID: 24846306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Post-transplant lymphoproliferative disorders in renal transplantation: two decades of experience].
    Franco A; Jiménez L; Sillero C; Trigueros M; González D; Alcaraz E; Olivares J
    Nefrologia; 2010; 30(6):669-75. PubMed ID: 21113217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.
    Chiusolo P; Metafuni E; Cattani P; Piccirillo N; Santangelo R; Manzara S; Bellesi S; De Michele T; Leone G; Sica S
    J Clin Immunol; 2010 Nov; 30(6):894-902. PubMed ID: 20737201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.
    Limaye AP; Huang ML; Atienza EE; Ferrenberg JM; Corey L
    J Clin Microbiol; 1999 Apr; 37(4):1113-6. PubMed ID: 10074534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.